Section Edited by Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzachanis, Kristen M O'Dwyer, Martha L Arellano, Yi Lin, Maria R BaerSee the full list of authors
30 August 2023
Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumorGe Gao, Weiting Liao, Pei Shu, Qizhi Ma, Xia He, Benxia Zhang, Diyuan Qin, Yongsheng Wang
17 August 2023
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapySiri Amanda Tvingsholm, Marcus Svensson Frej, Vibeke Mindahl Rafa, Ulla Kring Hansen, Maria Ormhøj, Alexander Tyron, Agnete W P Jensen, Mohammad Kadivar, Amalie Kai Bentzen, Kamilla K Munk, Gitte N Aasbjerg, Jeppe S H Ternander, Christina Heeke, Tripti Tamhane, Christian SchmessSee the full list of authors
16 August 2023
Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectinZhijie Zhang, Chang Liu, Muhan Wang, Rongcheng Sun, Zhe Yang, Zhen Hua, Yushuang Wu, Mengting Wu, Hang Wang, Wen Qiu, Hongping Yin, Meijia Yang
16 August 2023
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomasNicholas P Tschernia, Hillary Heiling, Allison M Deal, Catherine Cheng, Caroline Babinec, Megan Gonzalez, J Kaitlin Morrison, Christopher Dittus, Gianpietro Dotti, Anne W Beaven, Jonathan S Serody, William A Wood, Barbara Savoldo, Natalie S Grover
1 August 2023
Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemiaJingjing Wen, Yanxin Chen, Jiajie Yang, Chunye Dai, Shenjie Yu, Wenting Zhong, Lilin Liu, Chengguanng He, Wenmin Zhang, Ting Yang, Lingfeng Liu, Jianda Hu
31 July 2023
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapyLydia Lee, Wen Chean Lim, Daria Galas-Filipowicz, Kent Fung, Julia Taylor, Dominic Patel, Zulaikha Akbar, Elena Alvarez Mediavilla, Patrycja Wawrzyniecka, Debarati Shome, Rogier M Reijmers, Trillian Gregg, Leigh Wood, William Day, Virginie CerecSee the full list of authors
30 June 2023
BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer controlA J Robert McGray, Jessie L Chiello, Takemasa Tsuji, Mark Long, Kathryn Maraszek, Nicole Gaulin, Spencer R Rosario, Suzanne M Hess, Scott I Abrams, Danuta Kozbor, Kunle Odunsi, Emese Zsiros
23 June 2023
Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy studySophie Papa, Antonella Adami, Michael Metoudi, Richard Beatson, Molly Sarah George, Daniela Achkova, Evangelia Williams, Sefina Arif, Fiona Reid, Maria Elstad, Nicholas Beckley-Hoelscher, Abdel Douri, Marc Delord, Mike Lyne, Dharshene ShivapathamSee the full list of authors
15 June 2023
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicityJennifer Jess, Bonnie Yates, Alina Dulau-Florea, Kevin Parker, Jon Inglefield, Dan Lichtenstein, Fiorella Schischlik, Martin Ongkeko, Yanyu Wang, Shilpa Shahani, Ann Cullinane, Hannah Smith, Eli Kane, Lauren Little, Dong ChenSee the full list of authors
9 June 2023